View Past PerformanceTeraplast バランスシートの健全性財務の健全性 基準チェック /26Teraplastの総株主資本はRON423.5M 、総負債はRON395.1Mで、負債比率は93.3%となります。総資産と総負債はそれぞれRON1.2BとRON731.7Mです。 Teraplastの EBIT はRON5.5Mで、利息カバレッジ比率0.3です。現金および短期投資はRON20.5Mです。主要情報93.29%負債資本比率RON 395.06m負債インタレスト・カバレッジ・レシオ0.3x現金RON 20.51mエクイティRON 423.46m負債合計RON 731.69m総資産RON 1.16b財務の健全性に関する最新情報分析記事 • May 14Is Teraplast (BVB:TRP) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Dec 12Teraplast (BVB:TRP) Has A Somewhat Strained Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jun 27We Think Teraplast (BVB:TRP) Can Stay On Top Of Its DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...すべての更新を表示Recent updatesBuy Or Sell Opportunity • Jun 08Now 20% overvaluedOver the last 90 days, the stock has fallen 11% to RON0.43. The fair value is estimated to be RON0.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • May 19First quarter 2026 earnings released: RON0.003 loss per share (vs RON0 in 1Q 2025)First quarter 2026 results: RON0.003 loss per share (further deteriorated from RON0 in 1Q 2025). Revenue: RON239.4m (down 3.9% from 1Q 2025). Net loss: RON10.3m (down RON11.6m from profit in 1Q 2025). Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.分析記事 • Jan 29Teraplast S.A. (BVB:TRP) Might Not Be As Mispriced As It LooksIt's not a stretch to say that Teraplast S.A.'s ( BVB:TRP ) price-to-sales (or "P/S") ratio of 1.5x seems quite...Buy Or Sell Opportunity • Jan 28Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 21% to RON0.53. The fair value is estimated to be RON0.44, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Jan 24+ 4 more updatesTeraplast S.A. to Report Q1, 2026 Results on May 13, 2026Teraplast S.A. announced that they will report Q1, 2026 results on May 13, 2026Buy Or Sell Opportunity • Nov 21Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.9% to RON0.42. The fair value is estimated to be RON0.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Nov 03Third quarter 2025 earnings released: EPS: RON0.001 (vs RON0 in 3Q 2024)Third quarter 2025 results: EPS: RON0.001 (up from RON0 in 3Q 2024). Revenue: RON309.7m (up 22% from 3Q 2024). Net income: RON4.21m (up RON4.58m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 148 percentage points per year, which is a significant difference in performance.Price Target Changed • Sep 30Price target increased by 10% to RON0.41Up from RON0.38, the current price target is an average from 2 analysts. New target price is 5.5% below last closing price of RON0.44. Stock is up 11% over the past year. The company is forecast to post earnings per share of RON0 next year compared to a net loss per share of RON0.0067 last year.Reported Earnings • Aug 06Second quarter 2025 earnings released: EPS: RON0.001 (vs RON0.002 loss in 2Q 2024)Second quarter 2025 results: EPS: RON0.001 (up from RON0.002 loss in 2Q 2024). Revenue: RON312.3m (up 24% from 2Q 2024). Net income: RON1.20m (up RON5.30m from 2Q 2024). Profit margin: 0.4% (up from net loss in 2Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 146 percentage points per year, which is a significant difference in performance.分析記事 • Aug 02Further Upside For Teraplast S.A. (BVB:TRP) Shares Could Introduce Price Risks After 28% BounceTeraplast S.A. ( BVB:TRP ) shares have continued their recent momentum with a 28% gain in the last month alone. While...分析記事 • Jul 11Are Investors Undervaluing Teraplast S.A. (BVB:TRP) By 23%?Key Insights Teraplast's estimated fair value is RON0.64 based on 2 Stage Free Cash Flow to Equity Teraplast's RON0.49...分析記事 • May 23Teraplast S.A. (BVB:TRP) Soars 33% But It's A Story Of Risk Vs RewardTeraplast S.A. ( BVB:TRP ) shares have had a really impressive month, gaining 33% after a shaky period beforehand. But...Reported Earnings • May 15First quarter 2025 earnings released: EPS: RON0.001 (vs RON0.001 loss in 1Q 2024)First quarter 2025 results: EPS: RON0.001 (up from RON0.001 loss in 1Q 2024). Revenue: RON254.3m (up 44% from 1Q 2024). Net income: RON1.20m (up RON3.72m from 1Q 2024). Profit margin: 0.5% (up from net loss in 1Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 123 percentage points per year, which is a significant difference in performance.分析記事 • May 14Is Teraplast (BVB:TRP) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Buy Or Sell Opportunity • May 09Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to RON0.34. The fair value is estimated to be RON0.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.1% over the last 3 years. Meanwhile, the company became loss making.分析記事 • Apr 08A Look At The Intrinsic Value Of Teraplast S.A. (BVB:TRP)Key Insights The projected fair value for Teraplast is RON0.43 based on 2 Stage Free Cash Flow to Equity With RON0.35...お知らせ • Mar 27Teraplast S.A., Annual General Meeting, Apr 29, 2025Teraplast S.A., Annual General Meeting, Apr 29, 2025, at 10:00 E. Europe Standard Time. Location: at the companys headquarters of saratel, sieu-magherus commune, 1 teraplast way, bistrita-nasaud county, RomaniaNew Risk • Mar 04New major risk - Revenue and earnings growthEarnings have declined by 27% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 27% per year over the past 5 years.お知らせ • Jan 18+ 4 more updatesTeraplast S.A. to Report Q1, 2025 Results on May 13, 2025Teraplast S.A. announced that they will report Q1, 2025 results on May 13, 2025分析記事 • Dec 12Teraplast (BVB:TRP) Has A Somewhat Strained Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Nov 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.3x net interest cover). Earnings have declined by 18% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (10% increase in shares outstanding).Reported Earnings • Nov 01Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: RON254.8m (up 30% from 3Q 2023). Net loss: RON373.8k (down 105% from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 04Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: RON255.9m (up 48% from 2Q 2023). Net loss: RON4.09m (down 352% from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.Reported Earnings • May 13First quarter 2024 earnings released: RON0.001 loss per share (vs RON0.001 loss in 1Q 2023)First quarter 2024 results: RON0.001 loss per share (in line with 1Q 2023). Revenue: RON177.3m (up 20% from 1Q 2023). Net loss: RON2.53m (loss narrowed 3.7% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.New Risk • Feb 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 47% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.0x net interest cover). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.08% net profit margin).Reported Earnings • Feb 13Full year 2023 earnings released: EPS: RON0 (vs RON0.007 in FY 2022)Full year 2023 results: EPS: RON0 (down from RON0.007 in FY 2022). Revenue: RON674.2m (down 5.2% from FY 2022). Net income: RON541.0k (down 96% from FY 2022). Profit margin: 0.1% (down from 2.1% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Dec 19+ 5 more updatesTeraplast S.A. to Report Fiscal Year 2023 Final Results on Apr 26, 2024Teraplast S.A. announced that they will report fiscal year 2023 final results on Apr 26, 2024Reported Earnings • Oct 27Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: RON203.8m (up 7.3% from 3Q 2022). Net income: RON7.79m (up RON7.81m from 3Q 2022). Profit margin: 3.8% (up from 0% in 3Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 3.0% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.分析記事 • Sep 08There Could Be A Chance Teraplast S.A.'s (BVB:TRP) CEO Will Have Their Compensation IncreasedKey Insights Teraplast to hold its Annual General Meeting on 14th of September Total pay for CEO Alexandru Stânean...お知らせ • Aug 10Teraplast S.A., Annual General Meeting, Sep 14, 2023Teraplast S.A., Annual General Meeting, Sep 14, 2023, at 10:00 W. Europe Standard Time. Location: at the company's headquarters of Srael, ieu-Mgheru commune, 1 Teraplast Way Bistrita-Nasaud Romania Agenda: To consider establishing of the validity of the mandate of the members of the Board of Directors, starting with September 14, 2023. The Board of Directors proposes that mandate length will be 4 (four) years; to consider Mandating Mr. Alexandru Stânean and Mrs. Maria-Ioana Birta to negotiate and either to sign the Director Agreements with the directors, on behalf of the Company; to consider Electing an independent member of the Audit Committee for a one-year mandate starting from the date of appointment, in pursuance of Article 65 of title I, chapter IX, Law 162/2017, and establishing the remuneration; to consider and Approving the updated Remuneration Policy; and to consider other matter also.Reported Earnings • Jul 27Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: RON177.8m (down 13% from 2Q 2022). Net income: RON1.63m (down 83% from 2Q 2022). Profit margin: 0.9% (down from 4.7% in 2Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Feb 05Full year 2022 earnings released: EPS: RON0.007 (vs RON0.12 in FY 2021)Full year 2022 results: EPS: RON0.007 (down from RON0.12 in FY 2021). Revenue: RON716.1m (up 16% from FY 2021). Net income: RON15.4m (down 93% from FY 2021). Profit margin: 2.1% (down from 38% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 45% per year whereas the company’s share price has increased by 46% per year.お知らせ • Nov 26Teraplast S.A. to Report Fiscal Year 2022 Final Results on Apr 28, 2023Teraplast S.A. announced that they will report fiscal year 2022 final results on Apr 28, 2023お知らせ • Nov 25+ 4 more updatesTeraplast S.A., Annual General Meeting, Apr 28, 2023Teraplast S.A., Annual General Meeting, Apr 28, 2023.Price Target Changed • Nov 16Price target increased to RON0.99Up from RON0.87, the current price target is provided by 1 analyst. New target price is 92% above last closing price of RON0.52. Stock is down 55% over the past year. The company is forecast to post earnings per share of RON0.03 for next year compared to RON0.12 last year.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Lucian-Claudiu Anghel was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 28Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: RON193.3m (up 8.5% from 3Q 2021). Net loss: RON16.3k (down 100% from profit in 3Q 2021). Profit margin: 0% (down from 8.2% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth.Price Target Changed • Sep 15Price target increased to RON0.99Up from RON0.87, the current price target is provided by 1 analyst. New target price is 65% above last closing price of RON0.60. Stock is down 43% over the past year. The company is forecast to post earnings per share of RON0.03 for next year compared to RON0.12 last year.お知らせ • Aug 11Teraplast S.A., Annual General Meeting, Sep 14, 2022Teraplast S.A., Annual General Meeting, Sep 14, 2022, at 07:00 Coordinated Universal Time. Location: Srael, ieu-Mgheru commune, 1 Teraplast Way, Bistrita-Nasaud Romania Agenda: To consider election of the members of company's Board of Directors; to consider the establishing of the validity of the mandate of the members of the Board of Directors, starting with September 14, 2022; to consider Mandating Mr. Alexandru Stânean and Mrs. Maria-Ioana Birta to negotiate and either to sign the Director Agreements with the directors, on behalf of the company; to consider Agreements with the directors, on behalf of the Company Electing an independent member of the Audit Committee for a one-year mandate starting from the date of appointment, in pursuance of Article 65 of title I, chapter IX, Law 162/2017, and establishing the remuneration; to consider appointment of directors and other business related issues.Reported Earnings • Jul 28Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: RON205.0m (up 24% from 2Q 2021). Net income: RON9.54m (down 44% from 2Q 2021). Profit margin: 4.7% (down from 10% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 18%, compared to a 19% growth forecast for the industry in Romania. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 60% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Jul 01Upcoming dividend of RON0.015 per shareEligible shareholders must have bought the stock before 08 July 2022. Payment date: 29 July 2022. Trailing yield: 21%. Within top quartile of Romanian dividend payers (7.0%). Higher than average of industry peers (3.9%).分析記事 • May 07With EPS Growth And More, Teraplast (BVB:TRP) Is InterestingIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...Reported Earnings • May 05First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: RON171.5m (up 59% from 1Q 2021). Net income: RON6.87m (down 41% from 1Q 2021). Profit margin: 4.0% (down from 11% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 19%, compared to a 17% growth forecast for the industry in Romania. Over the last 3 years on average, earnings per share has increased by 76% per year whereas the company’s share price has increased by 78% per year.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Liviu Ciupe was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Buying Opportunity • Apr 04Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be RON1.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 26% over the last 3 years. Earnings per share has grown by 73%. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings is forecast to decline by 12% per annum over the same time period.お知らせ • Mar 29Teraplast S.A., Annual General Meeting, Apr 28, 2022Teraplast S.A., Annual General Meeting, Apr 28, 2022, at 08:00 Coordinated Universal Time. Location: Srael, ieu-Mgheru commune, 1 Teraplast Way, Bistria-Nsud county, postcode 427301 Bistrita-Nasaud Romania Agenda: To consider and approve the annual results of the company for the year ended December 31, 2021 and its publication; to consider the recommendation on the payment of a dividend, if any; to consider the recommendation on the payment of director remuneration; and to discuss other matters.分析記事 • Mar 23Calculating The Fair Value Of Teraplast S.A. (BVB:TRP)Today we will run through one way of estimating the intrinsic value of Teraplast S.A. ( BVB:TRP ) by taking the...Buying Opportunity • Mar 02Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 26%. The fair value is estimated to be RON1.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 26% per annum over the last 3 years. Earnings per share has grown by 73% per annum over the last 3 years.Major Estimate Revision • Feb 26Consensus EPS estimates fall by 25%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from RON845.0m to RON771.0m. EPS estimate also fell from RON0.04 per share to RON0.03 per share. Net income forecast to shrink 77% next year vs 15% growth forecast for Chemicals industry in Romania . Consensus price target down from RON0.91 to RON0.79. Share price fell 6.5% to RON0.93 over the past week.Reported Earnings • Oct 27Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: RON180.4m (down 45% from 3Q 2020). Net income: RON14.6m (down 53% from 3Q 2020). Profit margin: 8.1% (down from 9.3% in 3Q 2020). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Sep 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to RON1.27, the stock trades at a trailing P/E ratio of 31.1x. Average forward P/E is 18x in the Chemicals industry in Europe. Total returns to shareholders of 1,023% over the past three years.Valuation Update With 7 Day Price Move • Sep 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to RON1.26, the stock trades at a trailing P/E ratio of 24.5x. Average forward P/E is 19x in the Chemicals industry in Europe. Total returns to shareholders of 773% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at RON0.83 per share.分析記事 • Aug 29Should You Be Adding Teraplast (BVB:TRP) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...分析記事 • Aug 04Teraplast's (BVB:TRP) Robust Profit May Be Overstating Its True Earnings PotentialShareholders didn't seem to be thrilled with Teraplast S.A.'s ( BVB:TRP ) recent earnings report, despite healthy...Upcoming Dividend • Jul 05Upcoming dividend of RON0.13 per shareEligible shareholders must have bought the stock before 12 July 2021. Payment date: 22 July 2021. Trailing yield: 2.6%. Lower than top quartile of Romanian dividend payers (5.9%). Higher than average of industry peers (2.3%).分析記事 • Jun 27We Think Teraplast (BVB:TRP) Can Stay On Top Of Its DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Is New 90 Day High Low • Mar 15New 90-day high: RON0.69The company is up 61% from a price of RON0.43 on 15 December 2020. Outperformed the Romanian market which is up 12% over the last 90 days. Exceeded the Chemicals industry, which is up 7.0% over the same period. Simply Wall St's valuation model estimates the intrinsic value at RON0.46 per share.Is New 90 Day High Low • Feb 04New 90-day high: RON0.47The company is up 8.0% from its price of RON0.44 on 05 November 2020. The Romanian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is RON0.45 per share.分析記事 • Jan 25Shareholders of Teraplast (BVB:TRP) Must Be Delighted With Their 330% Total ReturnWhen you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...お知らせ • Dec 31Teraplast S.A. (BVB:TRP) acquired 70% stake in SC Somplast SA.Teraplast S.A. (BVB:TRP) acquired 70% stake in SC Somplast SA on December 29, 2020. The transaction was financed from the proceeds of selling the land for €1.3 million. Teraplast S.A. will take control over Somplast following the receipt of the Competition Council approval. Teraplast S.A. (BVB:TRP) completed the acquisition of 70% stake in SC Somplast SA on December 29, 2020.分析記事 • Dec 30How Much Of Teraplast S.A. (BVB:TRP) Do Insiders Own?A look at the shareholders of Teraplast S.A. ( BVB:TRP ) can tell us which group is most powerful. Institutions will...Upcoming Dividend • Dec 08Upcoming Dividend of RON0.026 Per ShareWill be paid on the 24th of December to those who are registered shareholders by the 15th of December. The company last paid an ordinary dividend in April 2018. The average dividend yield among industry peers is 2.6%.Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of RON131.7m, up 271% from the prior year. Total revenue was RON1.07b over the last 12 months, up 15% from the prior year.Is New 90 Day High Low • Oct 21New 90-day high: RON0.41The company is up 38% from its price of RON0.30 on 23 July 2020. The Romanian market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 2.0% over the same period.Price Target Changed • Sep 24Price target raised to RON0.46Up from RON0.34, the current price target is provided by 1 analyst. The new target price is 18% above the current share price of RON0.39. As of last close, the stock is up 92% over the past year.財務状況分析短期負債: TRPの 短期資産 ( RON503.6M ) が 短期負債 ( RON454.2M ) を超えています。長期負債: TRPの短期資産 ( RON503.6M ) が 長期負債 ( RON277.5M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: TRPの 純負債対資本比率 ( 88.5% ) は 高い と見なされます。負債の削減: TRPの負債対資本比率は、過去 5 年間で9.6%から93.3%に増加しました。債務返済能力: TRPの負債は 営業キャッシュフロー によって 十分にカバーされていません ( 0.5% )。インタレストカバレッジ: TRPの負債に対する 利息支払い は EBIT ( 0.3 x coverage) によって 十分にカバーされていません。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YMaterials 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 10:23終値2026/06/09 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Teraplast S.A. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Raluca FloreaErste Group Bank AGMihael AntolicInterCapital Securities Ltd.Matthias DesmaraisODDO BHF Corporate & Markets3 その他のアナリストを表示
分析記事 • May 14Is Teraplast (BVB:TRP) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Dec 12Teraplast (BVB:TRP) Has A Somewhat Strained Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Jun 27We Think Teraplast (BVB:TRP) Can Stay On Top Of Its DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Buy Or Sell Opportunity • Jun 08Now 20% overvaluedOver the last 90 days, the stock has fallen 11% to RON0.43. The fair value is estimated to be RON0.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • May 19First quarter 2026 earnings released: RON0.003 loss per share (vs RON0 in 1Q 2025)First quarter 2026 results: RON0.003 loss per share (further deteriorated from RON0 in 1Q 2025). Revenue: RON239.4m (down 3.9% from 1Q 2025). Net loss: RON10.3m (down RON11.6m from profit in 1Q 2025). Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
分析記事 • Jan 29Teraplast S.A. (BVB:TRP) Might Not Be As Mispriced As It LooksIt's not a stretch to say that Teraplast S.A.'s ( BVB:TRP ) price-to-sales (or "P/S") ratio of 1.5x seems quite...
Buy Or Sell Opportunity • Jan 28Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 21% to RON0.53. The fair value is estimated to be RON0.44, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Jan 24+ 4 more updatesTeraplast S.A. to Report Q1, 2026 Results on May 13, 2026Teraplast S.A. announced that they will report Q1, 2026 results on May 13, 2026
Buy Or Sell Opportunity • Nov 21Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.9% to RON0.42. The fair value is estimated to be RON0.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Nov 03Third quarter 2025 earnings released: EPS: RON0.001 (vs RON0 in 3Q 2024)Third quarter 2025 results: EPS: RON0.001 (up from RON0 in 3Q 2024). Revenue: RON309.7m (up 22% from 3Q 2024). Net income: RON4.21m (up RON4.58m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 148 percentage points per year, which is a significant difference in performance.
Price Target Changed • Sep 30Price target increased by 10% to RON0.41Up from RON0.38, the current price target is an average from 2 analysts. New target price is 5.5% below last closing price of RON0.44. Stock is up 11% over the past year. The company is forecast to post earnings per share of RON0 next year compared to a net loss per share of RON0.0067 last year.
Reported Earnings • Aug 06Second quarter 2025 earnings released: EPS: RON0.001 (vs RON0.002 loss in 2Q 2024)Second quarter 2025 results: EPS: RON0.001 (up from RON0.002 loss in 2Q 2024). Revenue: RON312.3m (up 24% from 2Q 2024). Net income: RON1.20m (up RON5.30m from 2Q 2024). Profit margin: 0.4% (up from net loss in 2Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 146 percentage points per year, which is a significant difference in performance.
分析記事 • Aug 02Further Upside For Teraplast S.A. (BVB:TRP) Shares Could Introduce Price Risks After 28% BounceTeraplast S.A. ( BVB:TRP ) shares have continued their recent momentum with a 28% gain in the last month alone. While...
分析記事 • Jul 11Are Investors Undervaluing Teraplast S.A. (BVB:TRP) By 23%?Key Insights Teraplast's estimated fair value is RON0.64 based on 2 Stage Free Cash Flow to Equity Teraplast's RON0.49...
分析記事 • May 23Teraplast S.A. (BVB:TRP) Soars 33% But It's A Story Of Risk Vs RewardTeraplast S.A. ( BVB:TRP ) shares have had a really impressive month, gaining 33% after a shaky period beforehand. But...
Reported Earnings • May 15First quarter 2025 earnings released: EPS: RON0.001 (vs RON0.001 loss in 1Q 2024)First quarter 2025 results: EPS: RON0.001 (up from RON0.001 loss in 1Q 2024). Revenue: RON254.3m (up 44% from 1Q 2024). Net income: RON1.20m (up RON3.72m from 1Q 2024). Profit margin: 0.5% (up from net loss in 1Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 123 percentage points per year, which is a significant difference in performance.
分析記事 • May 14Is Teraplast (BVB:TRP) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Buy Or Sell Opportunity • May 09Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to RON0.34. The fair value is estimated to be RON0.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.1% over the last 3 years. Meanwhile, the company became loss making.
分析記事 • Apr 08A Look At The Intrinsic Value Of Teraplast S.A. (BVB:TRP)Key Insights The projected fair value for Teraplast is RON0.43 based on 2 Stage Free Cash Flow to Equity With RON0.35...
お知らせ • Mar 27Teraplast S.A., Annual General Meeting, Apr 29, 2025Teraplast S.A., Annual General Meeting, Apr 29, 2025, at 10:00 E. Europe Standard Time. Location: at the companys headquarters of saratel, sieu-magherus commune, 1 teraplast way, bistrita-nasaud county, Romania
New Risk • Mar 04New major risk - Revenue and earnings growthEarnings have declined by 27% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 27% per year over the past 5 years.
お知らせ • Jan 18+ 4 more updatesTeraplast S.A. to Report Q1, 2025 Results on May 13, 2025Teraplast S.A. announced that they will report Q1, 2025 results on May 13, 2025
分析記事 • Dec 12Teraplast (BVB:TRP) Has A Somewhat Strained Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Nov 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.3x net interest cover). Earnings have declined by 18% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (10% increase in shares outstanding).
Reported Earnings • Nov 01Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: RON254.8m (up 30% from 3Q 2023). Net loss: RON373.8k (down 105% from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 04Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: RON255.9m (up 48% from 2Q 2023). Net loss: RON4.09m (down 352% from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 13First quarter 2024 earnings released: RON0.001 loss per share (vs RON0.001 loss in 1Q 2023)First quarter 2024 results: RON0.001 loss per share (in line with 1Q 2023). Revenue: RON177.3m (up 20% from 1Q 2023). Net loss: RON2.53m (loss narrowed 3.7% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.
New Risk • Feb 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 47% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.0x net interest cover). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.08% net profit margin).
Reported Earnings • Feb 13Full year 2023 earnings released: EPS: RON0 (vs RON0.007 in FY 2022)Full year 2023 results: EPS: RON0 (down from RON0.007 in FY 2022). Revenue: RON674.2m (down 5.2% from FY 2022). Net income: RON541.0k (down 96% from FY 2022). Profit margin: 0.1% (down from 2.1% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Dec 19+ 5 more updatesTeraplast S.A. to Report Fiscal Year 2023 Final Results on Apr 26, 2024Teraplast S.A. announced that they will report fiscal year 2023 final results on Apr 26, 2024
Reported Earnings • Oct 27Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: RON203.8m (up 7.3% from 3Q 2022). Net income: RON7.79m (up RON7.81m from 3Q 2022). Profit margin: 3.8% (up from 0% in 3Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 3.0% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
分析記事 • Sep 08There Could Be A Chance Teraplast S.A.'s (BVB:TRP) CEO Will Have Their Compensation IncreasedKey Insights Teraplast to hold its Annual General Meeting on 14th of September Total pay for CEO Alexandru Stânean...
お知らせ • Aug 10Teraplast S.A., Annual General Meeting, Sep 14, 2023Teraplast S.A., Annual General Meeting, Sep 14, 2023, at 10:00 W. Europe Standard Time. Location: at the company's headquarters of Srael, ieu-Mgheru commune, 1 Teraplast Way Bistrita-Nasaud Romania Agenda: To consider establishing of the validity of the mandate of the members of the Board of Directors, starting with September 14, 2023. The Board of Directors proposes that mandate length will be 4 (four) years; to consider Mandating Mr. Alexandru Stânean and Mrs. Maria-Ioana Birta to negotiate and either to sign the Director Agreements with the directors, on behalf of the Company; to consider Electing an independent member of the Audit Committee for a one-year mandate starting from the date of appointment, in pursuance of Article 65 of title I, chapter IX, Law 162/2017, and establishing the remuneration; to consider and Approving the updated Remuneration Policy; and to consider other matter also.
Reported Earnings • Jul 27Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: RON177.8m (down 13% from 2Q 2022). Net income: RON1.63m (down 83% from 2Q 2022). Profit margin: 0.9% (down from 4.7% in 2Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Feb 05Full year 2022 earnings released: EPS: RON0.007 (vs RON0.12 in FY 2021)Full year 2022 results: EPS: RON0.007 (down from RON0.12 in FY 2021). Revenue: RON716.1m (up 16% from FY 2021). Net income: RON15.4m (down 93% from FY 2021). Profit margin: 2.1% (down from 38% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 45% per year whereas the company’s share price has increased by 46% per year.
お知らせ • Nov 26Teraplast S.A. to Report Fiscal Year 2022 Final Results on Apr 28, 2023Teraplast S.A. announced that they will report fiscal year 2022 final results on Apr 28, 2023
お知らせ • Nov 25+ 4 more updatesTeraplast S.A., Annual General Meeting, Apr 28, 2023Teraplast S.A., Annual General Meeting, Apr 28, 2023.
Price Target Changed • Nov 16Price target increased to RON0.99Up from RON0.87, the current price target is provided by 1 analyst. New target price is 92% above last closing price of RON0.52. Stock is down 55% over the past year. The company is forecast to post earnings per share of RON0.03 for next year compared to RON0.12 last year.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Lucian-Claudiu Anghel was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 28Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: RON193.3m (up 8.5% from 3Q 2021). Net loss: RON16.3k (down 100% from profit in 3Q 2021). Profit margin: 0% (down from 8.2% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Sep 15Price target increased to RON0.99Up from RON0.87, the current price target is provided by 1 analyst. New target price is 65% above last closing price of RON0.60. Stock is down 43% over the past year. The company is forecast to post earnings per share of RON0.03 for next year compared to RON0.12 last year.
お知らせ • Aug 11Teraplast S.A., Annual General Meeting, Sep 14, 2022Teraplast S.A., Annual General Meeting, Sep 14, 2022, at 07:00 Coordinated Universal Time. Location: Srael, ieu-Mgheru commune, 1 Teraplast Way, Bistrita-Nasaud Romania Agenda: To consider election of the members of company's Board of Directors; to consider the establishing of the validity of the mandate of the members of the Board of Directors, starting with September 14, 2022; to consider Mandating Mr. Alexandru Stânean and Mrs. Maria-Ioana Birta to negotiate and either to sign the Director Agreements with the directors, on behalf of the company; to consider Agreements with the directors, on behalf of the Company Electing an independent member of the Audit Committee for a one-year mandate starting from the date of appointment, in pursuance of Article 65 of title I, chapter IX, Law 162/2017, and establishing the remuneration; to consider appointment of directors and other business related issues.
Reported Earnings • Jul 28Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: RON205.0m (up 24% from 2Q 2021). Net income: RON9.54m (down 44% from 2Q 2021). Profit margin: 4.7% (down from 10% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 18%, compared to a 19% growth forecast for the industry in Romania. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 60% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Jul 01Upcoming dividend of RON0.015 per shareEligible shareholders must have bought the stock before 08 July 2022. Payment date: 29 July 2022. Trailing yield: 21%. Within top quartile of Romanian dividend payers (7.0%). Higher than average of industry peers (3.9%).
分析記事 • May 07With EPS Growth And More, Teraplast (BVB:TRP) Is InterestingIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Reported Earnings • May 05First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: RON171.5m (up 59% from 1Q 2021). Net income: RON6.87m (down 41% from 1Q 2021). Profit margin: 4.0% (down from 11% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 19%, compared to a 17% growth forecast for the industry in Romania. Over the last 3 years on average, earnings per share has increased by 76% per year whereas the company’s share price has increased by 78% per year.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Liviu Ciupe was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Buying Opportunity • Apr 04Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be RON1.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 26% over the last 3 years. Earnings per share has grown by 73%. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings is forecast to decline by 12% per annum over the same time period.
お知らせ • Mar 29Teraplast S.A., Annual General Meeting, Apr 28, 2022Teraplast S.A., Annual General Meeting, Apr 28, 2022, at 08:00 Coordinated Universal Time. Location: Srael, ieu-Mgheru commune, 1 Teraplast Way, Bistria-Nsud county, postcode 427301 Bistrita-Nasaud Romania Agenda: To consider and approve the annual results of the company for the year ended December 31, 2021 and its publication; to consider the recommendation on the payment of a dividend, if any; to consider the recommendation on the payment of director remuneration; and to discuss other matters.
分析記事 • Mar 23Calculating The Fair Value Of Teraplast S.A. (BVB:TRP)Today we will run through one way of estimating the intrinsic value of Teraplast S.A. ( BVB:TRP ) by taking the...
Buying Opportunity • Mar 02Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 26%. The fair value is estimated to be RON1.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 26% per annum over the last 3 years. Earnings per share has grown by 73% per annum over the last 3 years.
Major Estimate Revision • Feb 26Consensus EPS estimates fall by 25%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from RON845.0m to RON771.0m. EPS estimate also fell from RON0.04 per share to RON0.03 per share. Net income forecast to shrink 77% next year vs 15% growth forecast for Chemicals industry in Romania . Consensus price target down from RON0.91 to RON0.79. Share price fell 6.5% to RON0.93 over the past week.
Reported Earnings • Oct 27Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: RON180.4m (down 45% from 3Q 2020). Net income: RON14.6m (down 53% from 3Q 2020). Profit margin: 8.1% (down from 9.3% in 3Q 2020). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Sep 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to RON1.27, the stock trades at a trailing P/E ratio of 31.1x. Average forward P/E is 18x in the Chemicals industry in Europe. Total returns to shareholders of 1,023% over the past three years.
Valuation Update With 7 Day Price Move • Sep 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to RON1.26, the stock trades at a trailing P/E ratio of 24.5x. Average forward P/E is 19x in the Chemicals industry in Europe. Total returns to shareholders of 773% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at RON0.83 per share.
分析記事 • Aug 29Should You Be Adding Teraplast (BVB:TRP) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
分析記事 • Aug 04Teraplast's (BVB:TRP) Robust Profit May Be Overstating Its True Earnings PotentialShareholders didn't seem to be thrilled with Teraplast S.A.'s ( BVB:TRP ) recent earnings report, despite healthy...
Upcoming Dividend • Jul 05Upcoming dividend of RON0.13 per shareEligible shareholders must have bought the stock before 12 July 2021. Payment date: 22 July 2021. Trailing yield: 2.6%. Lower than top quartile of Romanian dividend payers (5.9%). Higher than average of industry peers (2.3%).
分析記事 • Jun 27We Think Teraplast (BVB:TRP) Can Stay On Top Of Its DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Is New 90 Day High Low • Mar 15New 90-day high: RON0.69The company is up 61% from a price of RON0.43 on 15 December 2020. Outperformed the Romanian market which is up 12% over the last 90 days. Exceeded the Chemicals industry, which is up 7.0% over the same period. Simply Wall St's valuation model estimates the intrinsic value at RON0.46 per share.
Is New 90 Day High Low • Feb 04New 90-day high: RON0.47The company is up 8.0% from its price of RON0.44 on 05 November 2020. The Romanian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is RON0.45 per share.
分析記事 • Jan 25Shareholders of Teraplast (BVB:TRP) Must Be Delighted With Their 330% Total ReturnWhen you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
お知らせ • Dec 31Teraplast S.A. (BVB:TRP) acquired 70% stake in SC Somplast SA.Teraplast S.A. (BVB:TRP) acquired 70% stake in SC Somplast SA on December 29, 2020. The transaction was financed from the proceeds of selling the land for €1.3 million. Teraplast S.A. will take control over Somplast following the receipt of the Competition Council approval. Teraplast S.A. (BVB:TRP) completed the acquisition of 70% stake in SC Somplast SA on December 29, 2020.
分析記事 • Dec 30How Much Of Teraplast S.A. (BVB:TRP) Do Insiders Own?A look at the shareholders of Teraplast S.A. ( BVB:TRP ) can tell us which group is most powerful. Institutions will...
Upcoming Dividend • Dec 08Upcoming Dividend of RON0.026 Per ShareWill be paid on the 24th of December to those who are registered shareholders by the 15th of December. The company last paid an ordinary dividend in April 2018. The average dividend yield among industry peers is 2.6%.
Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of RON131.7m, up 271% from the prior year. Total revenue was RON1.07b over the last 12 months, up 15% from the prior year.
Is New 90 Day High Low • Oct 21New 90-day high: RON0.41The company is up 38% from its price of RON0.30 on 23 July 2020. The Romanian market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 2.0% over the same period.
Price Target Changed • Sep 24Price target raised to RON0.46Up from RON0.34, the current price target is provided by 1 analyst. The new target price is 18% above the current share price of RON0.39. As of last close, the stock is up 92% over the past year.